News
VRCA
5.92
-5.43%
-0.34
Weekly Report: what happened at VRCA last week (0706-0710)?
Weekly Report · 20h ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 5d ago
Weekly Report: what happened at VRCA last week (0629-0703)?
Weekly Report · 07/06 09:23
Weekly Report: what happened at VRCA last week (0622-0626)?
Weekly Report · 06/29 09:21
Verrica Doses First U.S. And Japanese Patients In Phase 3 COVE-3 Trial For YCANTH In Common Warts
NASDAQ · 06/22 16:45
H.C. Wainwright Sticks to Their Buy Rating for Verrica Pharmaceuticals (VRCA)
TipRanks · 06/22 14:15
Verrica doses first US patient in pivotal Phase 3 COVE-3 trial of YCANTH for common warts
PUBT · 06/22 12:05
VERRICA PHARMACEUTICALS ANNOUNCES FIRST U.S. PATIENT DOSED IN THE SECOND PIVOTAL CLINICAL TRIAL (COVE-3) OF ITS PHASE 3 PROGRAM EVALUATING YCANTH® (VP-102) FOR THE TREATMENT OF COMMON WARTS
Reuters · 06/22 12:05
Weekly Report: what happened at VRCA last week (0615-0619)?
Weekly Report · 06/22 09:24
Weekly Report: what happened at VRCA last week (0608-0612)?
Weekly Report · 06/15 09:24
Verrica’s COVE-3 Wart Study Moves Forward, Offering a Small but Notable Catalyst for VRCA and VEEV
TipRanks · 06/10 16:33
Verrica Shareholders Approve Governance Measures at Annual Meeting
TipRanks · 06/09 20:58
Verrica Pharmaceuticals shareholders approve amended 2018 equity incentive plan at annual meeting
PUBT · 06/09 20:06
Weekly Report: what happened at VRCA last week (0601-0605)?
Weekly Report · 06/08 09:23
Weekly Report: what happened at VRCA last week (0525-0529)?
Weekly Report · 06/01 09:24
Verrica Pharma CEO Jayson Rieger to present at Jefferies Global Healthcare Conference
PUBT · 05/28 12:09
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Barchart · 05/28 07:05
Verrica Pharmaceuticals Coverage Assumed by HC Wainwright & Co. at Buy
Dow Jones · 05/26 11:01
Verrica Pharmaceuticals Price Target Announced at $12.00/Share by HC Wainwright & Co.
Dow Jones · 05/26 11:01
HC Wainwright & Co. Assumes Verrica Pharmaceuticals at Buy, Announces Price Target of $12
Benzinga · 05/26 10:51
More
Webull provides a variety of real-time VRCA stock news. You can receive the latest news about Verrica Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About VRCA
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).